Your browser doesn't support javascript.
loading
Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up.
Luzzago, Stefano; Catellani, Michele; Di Trapani, Ettore; Cozzi, Gabriele; Mistretta, Francesco A; Bianchi, Roberto; Pricolo, Paola; Conti, Andrea; Ancona, Eleonora; Piacentini, Nicolò; Alessi, Sarah; Renne, Giuseppe; Ferro, Matteo; Matei, Deliu-Victor; Musi, Gennaro; Jereczek-Fossa, Barbara Alicja; Petralia, Giuseppe; de Cobelli, Ottavio.
Afiliación
  • Luzzago S; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy. stefanoluzzago@gmail.com.
  • Catellani M; Università degli Studi di Milano, Milan, Italy. stefanoluzzago@gmail.com.
  • Di Trapani E; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Cozzi G; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Mistretta FA; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Bianchi R; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Pricolo P; Università degli Studi di Milano, Milan, Italy.
  • Conti A; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Ancona E; Department of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Piacentini N; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Alessi S; Università degli Studi di Milano, Milan, Italy.
  • Renne G; Università degli Studi di Milano, Milan, Italy.
  • Ferro M; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Matei DV; Università degli Studi di Milano, Milan, Italy.
  • Musi G; Department of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Jereczek-Fossa BA; Department of Pathology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • Petralia G; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
  • de Cobelli O; Department of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy.
Prostate Cancer Prostatic Dis ; 23(1): 94-101, 2020 03.
Article en En | MEDLINE | ID: mdl-31249386
ABSTRACT

BACKGROUND:

To understand the value of multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies at recruitment on active surveillance (AS) outcomes. MATERIALS AND

METHODS:

This retrospective single-center study enrolled two cohorts of 206 and 310 patients in AS. The latter group was submitted to mpMRI and targeted biopsies at recruitment. Kaplan-meier curves quantified progression-free survival (PFS) and Bioptic-PFS (B-PFS no upgrading or >3 positive cores) in the two cohorts. Cox-regression analyses tested independent predictors of PFS and B-PFS. In patients submitted to radical prostatectomy (RP) after AS, significant cancer (csPCa) was defined as GS ≥ 4 + 3 and/or pT ≥ 3a and/or pN+ . Logistic-regression analyses predicted csPCa at RP. RESULTS AND

LIMITATIONS:

Median time follow-up and median time of persistence in AS were 46 (24-70) and 36 (23-58) months, respectively. Patients submitted to mpMRI at AS begin, showed greater PFS at 1- (98% vs. 91%), 3- (80% vs. 57%), and 5-years (70% vs. 35%) follow-up, respectively (all p < 0.01). At Cox-regression analysis only confirmatory mpMRI± targeted biopsy (HR 0.3; 95% CI 0.2-0.5; p < 0.01) at AS begin was an independent predictor of PFS. Globally, 50 (16%) vs. 128 (62%) and 26 (8.5%) vs. 64 (31%) [all p < 0.01] men in the two groups experienced any-cause and bioptic AS discontinuation, respectively. Patients submitted to confirmatory mpMRI experienced greater 1-(98% vs. 93%), 3-(90% vs. 75%), and 5-years (83% vs. 56%) B-PFS, respectively (all p < 0.01). At Cox-regression analysis, mpMRI±-targeted biopsy at AS begin was associated with B-PFS (HR 0.3; 95% CI 0.2-0.6; p < 0.01). No differences were recorded in csPCa rates between the two groups (22% vs. 28%; p = 0.47). Limitations of the study are the single-center retrospective nature and the absence of long-term follow-up.

CONCLUSIONS:

Confirmatory mpMRI±-targeted biopsies are associated with higher PFS and B-PFS during AS. However, a non-negligible percentage of patients experience csPCa after switching to active treatment.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Imágenes de Resonancia Magnética Multiparamétrica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Imágenes de Resonancia Magnética Multiparamétrica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia